Stay updated on Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision label changes from v3.7.2 to v3.8.0, while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-29T09:34:35.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    A sitewide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-22T08:29:28.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-15T11:58:37.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-08T13:42:23.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden error, blocking access to the study details that were previously visible on the page.
    Difference
    18%
    Check dated 2026-09-24T18:55:28.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The release notes now display Revision: v3.7.0, replacing the previous Revision: v3.6.6, indicating a new deployment of the page. This is a metadata/version update rather than a substantive modification to the study details.
    Difference
    0.0%
    Check dated 2026-09-17T22:07:49.000Z thumbnail image

Stay in the know with updates to Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.